RGL-2102

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameRGL-2102
Drug Alias NameRGL-2102RGL2102
ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > LNP
Mechanisms of ActionHepatocyte growth factor modulators
TargetsHepatocyte growth factor
Therapy Area/IndicationsUlcerIschemiaDiabetic Foot +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Regenelead Therapies Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Ruiling Pharmaceutical Co LtdShanghai Regenelead Therapies Co Ltd
Inactive CompaniesN/A
Active IndicationsUlcerIschemiaDiabetic Foot +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A